As the global economy mends, the 2021 growth of Evolocumab will have significant change from previous year. According to our (LP Information) latest study, the global Evolocumab market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Evolocumab market size will reach USD million in 2028, growing at a CAGR of % over the analysis period 2022-2028.
The United States Evolocumab market is expected at value of US$ million in 2021 and grow at approximately % CAGR during forecast period 2022-2028. China constitutes a % market for the global Evolocumab market, reaching US$ million by the year 2028. As for the Europe Evolocumab landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 6-year period.
Global main Evolocumab players cover BOCSCI, Carbosynth, TargetMol Chemicals, and Chemren Bio-Engineering, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Evolocumab market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022, in Section 2.3; and forecast to 2028 in section 12.6
Patent
Generic
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 12.7.
Chemical
Pharmaceutical
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the prominent manufacturers in this market, include
BOCSCI
Carbosynth
TargetMol Chemicals
Chemren Bio-Engineering
DC Chemicals
Hefei Enli Medical Technology
Hefei Hirisun Pharmatech
Hubei Kele Fine Chemical
Hubei Xingcheng Biotechnology
Hubei Zhongshan Medical Technology
Nantong Feiyu Biological Technology
Nantong Hi-Future Biotechnology
Shanghai Biochempartner
Shanghai Loulan Biotechnology
Shanghai Macklin Biochemical
Shanghai Minkai Biotechnology
Shanghai Ruihui Chemical Technology
Shanghai Yifei Biotechnology
Sichuan Weiqi Biotechnology
Taizhou KEDE Chemical
Taizhou Kerui Bio-Technology
WeiShi Reagent
Wuhan Fortuna Chemical
Wuhan Sunrise Technology Development
Wuhan Weisman Bioengineering
Wuhan Yingnuo Pharmaceutical Technology